Does Jardiance Cause Frequent Urination?
Yes, frequent urination is a common side effect of Jardiance (empagliflozin), a SGLT2 inhibitor used for type 2 diabetes, heart failure, and chronic kidney disease. It works by blocking glucose reabsorption in the kidneys, increasing glucose excretion in urine, which draws in more water and boosts urine volume—a process called osmotic diuresis.[1][2]
How Common Is It and Why Does It Happen?
Up to 10-15% of users report increased urination, especially early in treatment as the body adjusts. This peaks in the first few weeks and often lessens over time. Dehydration risk rises if fluid intake doesn't match output, so doctors advise drinking more water.[1][3]
What Do Patients Report?
Real-world experiences on forums and reviews match clinical data: many note needing bathroom breaks 2-3 times more often, particularly at night (nocturia). Some describe it as disruptive but tolerable; others switch meds if it persists.[4]
When Should You Worry?
Contact a doctor if urination becomes excessive (e.g., over 3 liters daily), causes dehydration signs like dizziness or dry mouth, or includes pain/blood—could signal urinary tract infection (UTI), another Jardiance risk affecting 5-10% of users.[1][2] It's not typical for everyone; factors like dose (10mg or 25mg) and kidney function influence it.
Managing Frequent Urination on Jardiance
- Increase water intake to 2-3 liters daily.
- Time doses in the morning to minimize nighttime trips.
- Limit evening fluids and caffeine/alcohol.
- Track symptoms; dose adjustment or add-ons like low-dose thiazides help some.[3][5]
Compared to Other Diabetes Meds
Jardiance causes more urination than metformin (rarely) or GLP-1s like Ozempic (mild), but less than loop diuretics. SGLT2 peers like Farxiga or Invokana have similar profiles.[2][6]
Sources
[1]: Jardiance Prescribing Information (FDA)
[2]: Drugs.com - Jardiance Side Effects
[3]: Mayo Clinic - Empagliflozin
[4]: Patient reviews aggregated from WebMD and Drugs.com
[5]: American Diabetes Association guidelines on SGLT2 inhibitors
[6]: Head-to-head data from clinical trials (e.g., EMPA-REG OUTCOME)